CytoMed Therapeutics (GDTC) Short Interest Ratio & Short Volume $2.46 +0.13 (+5.54%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock CytoMed Therapeutics Short Interest DataCytoMed Therapeutics (GDTC) has a short interest of 94,100 shares, representing 1.95% of the float (the number of shares available for trading by the public). This marks a -6.83% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.5, indicating that it would take 0.5 days of the average trading volume of 77,389 shares to cover all short positions.Current Short Interest94,100 sharesPrevious Short Interest101,000 sharesChange Vs. Previous Month-6.83%Dollar Volume Sold Short$207,020.00Short Interest Ratio0.5 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares10,940,000 sharesFloat Size4,830,000 sharesShort Percent of Float1.95%Today's Trading Volume1,162 sharesAverage Trading Volume77,389 sharesToday's Volume Vs. Average2% Short Selling CytoMed Therapeutics? Sign up to receive the latest short interest report for CytoMed Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGDTC Short Interest Over TimeGDTC Days to Cover Over TimeGDTC Percentage of Float Shorted Over Time CytoMed Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202594,100 shares $207,020.00 -6.8%2.0%0.5 $2.20 3/15/2025101,000 shares $250,480.00 -21.0%2.1%0.5 $2.48 2/28/2025127,800 shares $350,172.00 -13.5%3.2%0.6 $2.74 2/15/2025147,800 shares $378,368.00 -22.5%3.1%0.7 $2.56 1/31/2025190,600 shares $503,184.00 -15.6%4.0%1 $2.64 1/15/2025225,900 shares $494,721.00 +174.8%4.7%1.1 $2.19 12/31/202482,200 shares $279,480.00 +31.1%1.7%0.4 $3.40 12/15/202462,700 shares $170,261.85 -17.1%1.3%3.2 $2.72 11/30/202475,600 shares $177,660.00 -1.6%1.6%4.4 $2.35 11/15/202476,800 shares $166,986.24 -19.4%1.6%6.3 $2.17 Get the Latest News and Ratings for GDTC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/202495,300 shares $229,673.00 -17.9%2.0%7.7 $2.41 10/15/2024116,100 shares $241,488.00 -2.4%2.5%10 $2.08 9/30/2024118,900 shares $186,673.00 -3.1%2.5%1.7 $1.57 9/15/2024122,700 shares $184,050.00 -2.3%2.6%1.9 $1.50 8/31/2024125,600 shares $186,051.28 +5.3%2.7%1.9 $1.48 8/15/2024119,300 shares $206,389.00 -9.4%2.5%1.8 $1.73 7/31/2024131,600 shares $238,196.00 +240.9%2.8%2 $1.81 7/15/202438,600 shares $77,200.00 -1.8%0.8%0.6 $2.00 6/30/202439,300 shares $81,744.00 +1.3%0.8%10.1 $2.08 6/15/202438,800 shares $73,720.00 +9.9%0.8%8.6 $1.90 5/31/202435,300 shares $76,248.00 -8.3%0.8%5.8 $2.16 5/15/202438,500 shares $85,855.00 -10.3%1.0%5.4 $2.23 4/30/202442,900 shares $90,519.00 +8.9%1.1%3 $2.11 4/15/202439,400 shares $79,588.00 +11.6%1.0%1.6 $2.02 3/31/202435,300 shares $76,601.00 +82.9%0.9%1.2 $2.17 3/15/202419,300 shares $41,109.00 No Change0.5%0.4 $2.13 2/29/202419,300 shares $38,793.00 -15.7%0.5%0.4 $2.01 2/15/202422,900 shares $57,479.00 +593.9%0.6%0.4 $2.51 1/31/20243,300 shares $11,682.00 -58.2%0.1%0.1 $3.54 1/15/20247,900 shares $32,627.00 -54.3%0.2%0.2 $4.13 12/31/202317,300 shares $84,770.00 +1,135.7%0.4%0.5 $4.90 12/15/20231,400 shares $4,746.00 -63.2%0.0%0.1 $3.39 11/30/20233,800 shares $14,022.00 +245.5%0.1%0.6 $3.69 11/15/20231,100 shares $4,411.00 -54.2%0.0%0.2 $4.01 10/31/20232,400 shares $8,952.00 -50.0%0.1%0.2 $3.73 10/15/20234,800 shares $16,944.00 -20.0%0.1%0.3 $3.53 9/30/20236,000 shares $21,000.00 -25.9%0.2%0 $3.50 9/15/20238,100 shares $30,456.00 -5.8%0.2%0 $3.76 8/31/20238,600 shares $28,982.00 +30.3%0.2%0 $3.37 8/15/20236,600 shares $24,882.00 -50.0%0.2%0 $3.772025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis (Ad)What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years. Click here to see Dan's full warning to the public. 7/31/202313,200 shares $57,156.00 -92.2%0.3%0 $4.33 7/15/2023169,600 shares $736,064.00 +198.6%4.3%0.3 $4.34 6/30/202356,800 shares $173,240.00 +24.6%1.5%0.1 $3.05 6/15/202345,600 shares $129,504.00 -27.2%1.2%0.3 $2.84 5/31/202362,600 shares $170,898.00 +67.8%1.8%0.3 $2.73 5/15/202337,300 shares $114,884.00 No Change1.1%0.1 $3.08 GDTC Short Interest - Frequently Asked Questions What is CytoMed Therapeutics' current short interest? Short interest is the volume of CytoMed Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, traders have sold 94,100 shares of GDTC short. 1.95% of CytoMed Therapeutics' shares are currently sold short. Learn More on CytoMed Therapeutics' current short interest. What is a good short interest percentage for CytoMed Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.95% of CytoMed Therapeutics' floating shares are currently sold short. Is CytoMed Therapeutics' short interest increasing or decreasing? CytoMed Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 94,100 shares, a drop of 6.8% from the previous total of 101,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is CytoMed Therapeutics' float size? CytoMed Therapeutics currently has issued a total of 10,940,000 shares. Some of CytoMed Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. CytoMed Therapeutics currently has a public float of 4,830,000 shares. How does CytoMed Therapeutics' short interest compare to its competitors? 1.95% of CytoMed Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to CytoMed Therapeutics: Alector, Inc. (7.26%), Seres Therapeutics, Inc. (9.88%), XBiotech Inc. (3.97%), Senti Biosciences, Inc. (0.78%), Tiziana Life Sciences Ltd (1.05%), Elutia Inc. (0.26%), Anixa Biosciences, Inc. (1.26%), OptiNose, Inc. (2.42%), Oramed Pharmaceuticals Inc. (1.87%), Coya Therapeutics, Inc. (1.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short CytoMed Therapeutics stock? Short selling GDTC is an investing strategy that aims to generate trading profit from CytoMed Therapeutics as its price is falling. GDTC shares are trading up $0.13 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CytoMed Therapeutics? A short squeeze for CytoMed Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GDTC, which in turn drives the price of the stock up even further. How often is CytoMed Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GDTC, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies ALEC Short Interest MCRB Short Interest XBIT Short Interest SNTI Short Interest TLSA Short Interest ELUT Short Interest ANIX Short Interest OPTN Short Interest ORMP Short Interest COYA Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GDTC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.